Covetrus Announces Retirement of Matthew Foulston

$CVET
Other Pharmaceuticals
Health Care
Get the next $CVET alert in real time by email

Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced that Matthew Foulston, the Company's Executive Vice President and Chief Financial Officer, has informed the company that he will be retiring from the company effective December 31, 2022.

Foulston's role at Covetrus caps off a strong career in which he has led technical, strategic and operational finance teams within a broad range of manufacturing, distribution and automotive companies. Since joining Covetrus in 2020, Foulston's leadership and depth of experience served the company well. "Matthew is a strong financial partner to our business, our leadership, our Board, and me. Plus, he's a great advocate for our employees – one example being his development of the intern and mentoring programs that will extend beyond the finance team throughout the organization. So, while I will be sorry to see Matthew leave, it's clear his impact will continue long after his final day at Covetrus," said Ben Wolin, President and CEO of Covetrus. "We appreciate Matthew's many contributions, and we wish him much enjoyment in his well-earned retirement."

"It has been great to finish up my career working with such a talented team in such a dynamic industry," Foulston said. "The sense of purpose and the long runway ahead for this business make Covetrus a very compelling place to work, and I look forward to seeing the Company's continued growth and great success."

A search for the role of Chief Financial Officer is underway, and Foulston is assisting in the process to ensure a smooth transition to his successor.

About Covetrus

Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine with more than 5,700 employees serving over 100,000 customers around the globe. For more information about Covetrus visit https://covetrus.com/.

Forward-Looking Statements

This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the Securities and Exchange Commission. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.

Get the next $CVET alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CVET

DatePrice TargetRatingAnalyst
6/13/2022$22.00Buy → Hold
Stifel
5/23/2022Outperform → Mkt Perform
Raymond James
11/18/2021$19.00Equal-Weight
Morgan Stanley
11/5/2021$37.00 → $27.00Outperform
Raymond James
8/9/2021$46.00 → $38.00Overweight
Barclays
8/6/2021$38.00 → $37.00Outperform
Raymond James
8/5/2021$29.00Neutral
Credit Suisse
7/12/2021$30.00Neutral → Buy
Guggenheim
More analyst ratings

$CVET
Press Releases

Fastest customizable press release news feed in the world

See more
  • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

    Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

    $SEMR
    $CVET
    Computer Software: Prepackaged Software
    Technology
    Other Pharmaceuticals
    Health Care
  • Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600

    NEW YORK, Oct. 13, 2022 /PRNewswire/ -- Westlake Corp. (NYSE:WLK) will replace MillerKnoll Inc. (NASD:MLKN) in the S&P MidCap 400, and MillerKnoll will replace Covetrus Inc. (NASD:CVET) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 18. Clayton, Dubilier & Rice and TPG Capital acquired Covetrus in a deal that closed today. MillerKnoll is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 18, 2022 S&P MidCap 400 Addition Westlake WLK Materials S&P MidCap 400 Deletion Miller

    $CVET
    $MLKN
    $SPGI
    $WLK
    Other Pharmaceuticals
    Health Care
    Office Equipment/Supplies/Services
    Consumer Discretionary
  • Covetrus Names Michelle Bonfilio as Chief People Officer

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

    $CVET
    Other Pharmaceuticals
    Health Care

$CVET
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CVET
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CVET
SEC Filings

See more

$CVET
Leadership Updates

Live Leadership Updates

See more
  • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

    Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

    $SEMR
    $CVET
    Computer Software: Prepackaged Software
    Technology
    Other Pharmaceuticals
    Health Care
  • Covetrus Names Michelle Bonfilio as Chief People Officer

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

    $CVET
    Other Pharmaceuticals
    Health Care
  • Covetrus Names Margie B. Pritchard General Counsel

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. Prior to being named as General Counsel, Pritchard most recently served as Vice President, Deputy Counsel at Covetrus, where she was responsible for corporate and board governance, public reporting, advising investor relations, employment matters including compensation, and providing general legal counsel to executive management. "Margie has been serving as Interim General Counsel since December 2021, and we are thrilled to have h

    $CVET
    Other Pharmaceuticals
    Health Care

$CVET
Financials

Live finance-specific insights

See more
  • Covetrus Announces Financial Results for Second Quarter of 2022

    Second quarter 2022 net sales of $1.22 billion, an increase of 2% year-over-year; GAAP net loss attributable to Covetrus of $(4) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA was flat year-over-year at $66 million, including a $2 million year-over-year headwind from the strengthening of the U.S. Dollar First half 2022 net sales of $2.37 billion, an increase of 3% year-over-year; GAAP net loss attributable to Covetrus of $(6) million Non-GAAP organic net sales growth of 6% year-over-year Non-GAAP adjusted EBITDA increased 5% year-over-year to $129 million, including a $4 million year-over-year headwind from the strengthening of the U.S.

    $CVET
    Other Pharmaceuticals
    Health Care
  • Covetrus Announces First Quarter 2022 Earnings Release Date and Conference Call Information

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release first quarter 2022 results after the market closes on Thursday, May 5, 2022. Following the release, the Company will hold a conference call at 4:30 PM ET, during which Ben Wolin, president and chief executive officer, and Matthew Foulston, executive vice president and chief financial officer, will review the results. To access the live webcast of the conference call and the corresponding slide presentation, individuals can register at our Investor Relations site: https://ir.covetrus.com/investors/events-and-presentations. An archived edition of the conference call will be

    $CVET
    Other Pharmaceuticals
    Health Care
  • Covetrus Announces Financial Results for Fourth Quarter and Full-Year of 2021

    Fourth quarter 2021 net sales of $1.12 billion, unchanged year-over-year; GAAP net loss attributable to Covetrus of $(3) million Non-GAAP organic net sales growth of 2% year-over-year Non-GAAP adjusted EBITDA increased 13% year-over-year to $63 million Full-year 2021 net sales of $4.58 billion, an increase of 5% year-over-year; GAAP net loss attributable to Covetrus of $(54) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA increased 8% year-over-year to $244 million 2022 non-GAAP organic net sales growth guidance of 7% to 8% and non-GAAP adjusted EBITDA guidance in the range of $270 million to $280 million Covetrus® (NASDAQ:CVET), a

    $CVET
    Other Pharmaceuticals
    Health Care

$CVET
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more